Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases

• US 5,753,227 A
• Filed: 07/23/1993
• Issued: 05/19/1998
• Est. Priority Date: 07/23/1993
• Status: Expired due to Term

• Current Assignee: Meir Strahilevitz
• Original Assignee: Meir Strahilevitz
• Inventors: Strahilevitz, Meir
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US08/097,378
• Time in Patent Office: 1,761 Days
• Field of Search: 424/140.1, 210/638, 210/645, 210/646, 210/660, 210/661, 210/688, 210/648, 210/651, 210/670, 604/5, 604/6
• US Class Current: 424/140.1
• CPC Class Codes: A61M 1/3475 with filtrate treatment agent in the same enclosure as the membrane
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 1/362 changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders

Abstract

Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.

Claims

1. A method of treating atherosclerosis comprising a step of placing in an extracorporeal adsorption device at least one chelant which binds selectively with a metal ion oxidant, and a step of connecting the device in the blood circulatory system of a mammal to expose at least a portion of the blood of the mammal containing said metal ion to said chelant.

2. The method of claim 1 wherein the metal ion is selected from the group consisting of copper and iron.

3. The method of claim 1 wherein the adsorption device includes means for immobilizing said chelant on a matrix.

4. The method of claim 1 wherein the adsorption device is a pressure assisted filtration device including at least one semipermeable membrane.

5. The method of claim 4 wherein the semipermeable membrane is in the form of a hollow fiber.

6. The method of claim 5 wherein the semipermeable membrane comprises a plurality of hollow fibers.

13. The method of claim 1 wherein the specific affinity adsorbent binds immunologically.

14. The method of claim 1 wherein the disease state is atherosclerosis.

15. The method of claim 14 wherein the specific affinity adsorbent binds a chemical species selected from the group consisting of cholesterol, LDL, oxidized LDL, and antibodies to oxidized LDL.

7. A method of treating atherosclerosis comprising a step of placing in an extracorporeal affinity adsorption device at least two specific affinity adsorbents, one of said specific affinity adsorbents binding selectively with a first chemical species which is etiological to atherosclerosis and a second of said specific affinity adsorbents binding selectively with a second chemical species which is etiological to atherosclerosis, and a step of connecting the device in the blood circulatory system of a mammal to expose at least a portion of the blood of the mammal containing both said chemical species to said specific affinity adsorbents.

8. The method of claim 7 wherein the specific affinity adsorbents are prevented from entering the circulatory system by a semipermeable membrane.

9. An extracorporeal device for treating a disease state in a living mammal, the disease state being characterized by having a first chemical species comprising a metal ion oxidant etiological to the disease state or its symptoms and a second chemical species which is etiological to the disease state or to its symptoms, the device including means for drawing from the mammal a fluid containing the metal ion oxidant and the second chemical species, means for exposing the fluid to at least a first chelant binding means for chemically binding said metal ion oxidant in said device and to a second binding means for chemically binding said second chemical species in said device, and means for returning to the mammal at least a fraction of said fluid.

10. A method for treating a disease state in a living mammal, the disease state being characterized by having a first chemical species comprising a metal ion oxidant etiological to the disease state or its symptoms and a second chemical species which is etiological to the disease state or to its symptoms, the method comprising drawing from the mammal a fluid containing the metal ion oxidant and the second chemical species into an extracorporeal device, exposing the fluid to at least a chelant for chemically binding said first chemical species in said device, exposing the fluid to a specific affinity adsorbent for chemically binding said second chemical species in said device, and returning to the mammal at least a fraction of said fluid.

11. The method of claim 10 wherein the fluid is exposed simultaneously to the chelant and the specific affinity adsorbent.

12. The method of claim 10 wherein the fluid is exposed sequentially to the chelant and the specific affinity adsorbent.

16. The method of claim 10 wherein the disease state is autoimmune disease, and the specific affinity adsorbent binds a chemical species selected from the group consisting of autoantibodies and immune complexes.

17. The method of claim 16 wherein the specific affinity adsorbent binds immunologically.

18. The method of claim 10 wherein said specific affinity adsorbent is selected from the group consisting of Protein A, Protein G, and C1q bound to anti-C1q antibody.

19. The method of claim 10 wherein the disease state is cancer.

20. The method of claim 10 wherein said specific affinity adsorbent is a non-immunological chemical affinity adsorbent.

21. A method for treating a disease state in a living mammal, the disease state being characterized by having at least a first chemical species and a second chemical species which are etiological to the disease state or to its symptoms, the method comprising drawing from the mammal a fluid containing both the chemical species into an extracorporeal device, exposing the fluid to at least a first specific affinity adsorbent for chemically binding said first chemical species in said device, exposing the fluid to a second specific affinity adsorbent for chemically binding said second chemical species in said device, returning to the mammal at least a fraction of said fluid, and a further step of administering to the living mammal intravenously at least one plasma component.

22. The method of claim 21 wherein said plasma component is gamma globulin.

23. A method of treating atherosclerosis comprising a step of placing in an extracorporeal affinity adsorption device at least one chemical substance which binds selectively with autoantibodies to oxidized low density lipoproteins, and a step of connecting the device in the blood circulatory system of a mammal to expose at least a portion of the blood of the mammal containing autoantibodies to oxidized low density lipoproteins to said chemical substance.

24. The method of claim 23 wherein the chemical substance is selected from the group consisting of oxidized low density lipoprotein, Protein A, Protein G, and C1q bound to anti-C1q antibody.

25. An extracorporeal device including means for drawing from a mammal a fluid, chelant means in said device for exposing at least a portion of the fluid to a chelating agent for binding a metal ion and a specific affinity adsorbent in said device for chemically binding at least one chemical species in said fluid, and means for returning to the mammal at least a fraction of said fluid.

26. The device of claim 25 including a semipermeable membrane for preventing the specific affinity adsorbent from entering the body of the mammal.

27. The device of claim 26 wherein said fluid is blood, the device including means for attaching the device into the blood circulatory system of the mammal.

28. The device of claim 25 including at least two semipermeable membranes of different permeabilities.

29. The device of claim 25 wherein said at least a portion of said fluid is plasma.

30. The device of claim 25 including means for exposing the fluid simultaneously to the chelant and the specific affinity binding means.

31. The device of claim 25 including means for exposing said fluid sequentially to the chelant and the specific affinity binding means.

32. The device of claim 25 wherein the specific affinity binding means binds immunologically.

33. The device of claim 25 wherein said chelant binds a metal selected from the group consisting of iron and copper.

34. The device of claim 25 wherein the specific affinity binding means binds a species, selected from the group consisting of cholesterol, LDL, oxidized LDL and antibodies to oxidized LDL.

35. The device of claim 25 wherein the specific affinity binding means binds a chemical species selected from the group consisting of autoantibodies and immune complexes.

36. The device of claim 25 wherein the specific affinity binding means is selected from the group consisting of Protein A, Protein G, and C1q bound to anti-C1q antibody.

37. The device of claim 25 wherein the specific affinity binding means is a non-immunological chemical affinity adsorbent.

38. The device of claim 25 wherein the specific affinity binding means is an antibody to an anticancer drug or a fragment of such antibody.

39. The device of claim 38 wherein said drug is adriamycin.

40. The device of claim 25 wherein the specific affinity binding means binds to a moiety consisting of an anticancer drug and a targeting antibody chemically bound to said anticancer drug directly or through a spacer, said targeting antibody being an intact antibody or a fragment of an antibody.

41. The device of claim 40 in which said specific affinity binding means is an antibody specific to said drug in the drug-targeting antibody moiety or a fragment of such antibody.

42. The device of claim 40 wherein said specific affinity binding means is an antibody specific to a tumor or tissue targeting antibody in the drug-targeting antibody moiety, or a fragment of such antibody.

43. The device of claim 40 wherein said specific affinity binding means is tumor antigen or tissue antigen, or fetal antigen to which the targeting antibody is directed.

44. The device of claim 43 wherein said specific affinity binding means is human-alpha-fetoprotein.

45. The device of claim 40 wherein said drug in the anticancer drug targeting antibody moiety is adriamycin.

46. The device of claim 40 wherein said drug is radioactive.

47. A method for treating a disease state in a living mammal, the disease state being characterized by having at least a first chemical species and a second chemical species which are etiological to the disease state or to its symptoms, the method comprising drawing from the mammal a fluid containing both the chemical species into an extracorporeal device exposing the fluid to at least a first adsorbent for chemically binding the first chemical species in the device and to a second adsorbent for chemically binding the second chemical species in the device returning to the mammal at least a fraction of the fluid, and thereafter regenerating the device for further use by connecting a regenerating fluid to the device at least one of the adsorbents being a specific affinity adsorbent, the other adsorbent being a chelant.

48. The method of claim 47 wherein the fluid is exposed simultaneously to the specific affinity adsorbent and the chelant.

49. The method of claim 47 wherein the fluid is exposed sequentially to the specific affinity adsorbent and the chelant.

50. The method of claim 47 wherein the specific affinity adsorbent binds immunologically.

51. The method of claim 47 wherein the disease state is selected from the group consisting of rheumatoid arthritis and other autoimmune disease, and the specific affinity adsorbent binds a chemical species selected from the group consisting of autoantibodies and immune complexes.

52. The method of claim 47 wherein the specific affinity adsorbent is selected from the group consisting of Protein A, Protein G, and C1q bound to anti-C1q antibody.

53. The method of claim 47 wherein the specific affinity adsorbent is a non-immunological chemical affinity adsorbent.

54. A method for treating a disease state in a living mammal, the disease state being characterized by having at least a first chemical species and a second chemical species which are etiological to the disease state or to its symptoms, the method comprising drawing from the mammal a fluid containing both the chemical species into an extracorporeal device, exposing the fluid to at least a first adsorbent for chemically binding selectively with the first chemical species in the device and to a second adsorbent for chemically binding selectively with the second chemical species in the device, returning to the mammal at least a fraction of the fluid, and thereafter regenerating the device for further use by connecting a regenerating fluid to the device, wherein the disease state is atherosclerosis.

55. The method of claim 54 wherein one of the adsorbents binds selectively with a chemical species selected from the group consisting of cholesterol, LDL, oxidized LDL, and antibodies to oxidized LDL.

56. A method for treating a disease state in a living mammal, the disease state being characterized by having at least a first chemical species and a second chemical species which are etiological to the disease state or to its symptoms, the method comprising drawing from the mammal a fluid containing both the chemical species into an extracorporeal device, exposing the fluid to at least a first adsorbent for chemically binding the first chemical species in the device and to a second adsorbent for chemically binding the second chemical species in the device, returning to the mammal at least a fraction of the fluid, and thereafter regenerating the device for further use by connecting a regenerating fluid to the device, and a further step of administering to the living mammal intravenously at least one plasma component.

57. The method of claim 56 wherein the plasma component is gamma globulin.

58. A method of treating a disease state selected from the group consisting of cancer and autoimmune disease, the method comprising a step of placing in an extracorporeal adsorption device at least one chelant which binds selectively with a metal ion oxidant, and a step of connecting the device in the blood circulatory system of a mammal to expose at least a portion of the blood of the mammal containing said metal ion to said chelant.

59. The method of claim 58 wherein the disease state is cancer.

60. The method of claim 58 wherein the disease state is rheumatoid arthritis.

61. The method of claim 58 wherein the metal ion is selected from the group consisting of iron and copper.

62. A method of treating an autoimmune disease, the method comprising a step of placing in an extracorporeal adsorption device at least one chelant which binds selectively with a metal ion oxidant, and a step of connecting the device in the blood circulatory system of a mammal to expose at least a portion of the blood of the mammal containing said metal ion to said chelant.